The 13 participating EU countries.

Baxter announces European rMRP approval of PREFLUCEL seasonal influenza vaccine Baxter International Inc. Announced today the acceptance of a European do it again mutual recognition treatment by the Austrian Company for Health insurance and Food Security for Baxter’s PREFLUCEL seasonal influenza vaccine. The 13 participating EU countries, including Germany, Spain, UK and Nordic countries, will formally put into action the permit on a nationwide level to create PREFLUCEL designed for the 2011-12 influenza period. PREFLUCEL, a seasonal vaccine made up of purified, inactivated split influenza virions, may be the consequence of dedicated product advancement efforts to supply a well-tolerated and effective innovative vaccine which can be dependably produced for each influenza period.This material is probably not published, broadcast, rewritten or redistributed.. CVBT seeks FDA ‘fast track’ designation for CVBT-141B to treat ischemic diabetic wounds CardioVascular BioTherapeutics, Inc. today announced it has submitted an application to the U.S. FDA to acquire fast track designation for CVBT-141B, its biological therapy to treat ischemic diabetic wounds based on the active component fibroblast growth factor-1 . CVBT believes CVBT-141B meets the FDA’s requirements, as ischemic diabetic wounds, if not treated successfully, can lead to disease, sepsis, amputation, and loss of life. Related StoriesMayo Clinic investigators discover novel mechanism linked to diabetes riskDiabetes prevention starts in the wombHeart attack patients diagnosed and treated for diabetes knowledge improved cardiac outcomesCVBT’s CEO, Daniel C.

Other Posts From "pharmacy":

Related Posts